Sanai FM, et al. - This study examined the real-world safety and efficacy of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) in genotype (GT)-1 and 4-infected patients with chronic kidney disease (CKD) stages 4-5 (<30 mL/min/1.73 m²). Findings revealed that 65 (97.1%) patients achieved SVR12, including 100% of those with a post-treatment follow-up (modified intention-to-treat (ITT) analysis). It was determined that a 12-week regimen of OBV/PTV/r ± DSV with or without RBV was highly effective. Such a regimen demonstrated a favourable safety profile amongst GT4 and GT1 patients with CKD stages 4-5. Irrespective of patient characteristics, SVR12 rates were discovered to be high.